WebJun 21, 2024 · TARRYTOWN, N.Y. and PARIS, June 21, 2024 /PRNewswire/ -- REGN3500 monotherapy significantly reduced loss of asthma control and improved lung function compared to placebo. Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that a Phase 2 proof-of-concept trial evaluating the investigational IL … WebJun 30, 2024 · Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma The safety and scientific validity of this study is the responsibility of …
CSJ117 on Pulmonary Disease, Chronic Obstructive - Clinical Trials ...
WebJun 1, 2024 · Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma The safety and scientific validity of this study is the responsibility of the study … WebSep 1, 2024 · All 4 treatment groups were well matched by baseline asthma characteristics and demographics (Table I).The majority of patients were female (66.1%) and White (84.1%), median age was 53 years (range 18-75 years), and median body mass index was 27.94 kg/m 2 (range 18.4-37.0 kg/m 2).Per the eligibility criteria, all patients used daily … nothum intranet
CSJ117 on Asthma - Clinical Trials Registry - ICH GCP
WebMethods: This study was a proof-of-concept, randomized, double-blind, placebo-controlled study performed in mild asthmatics, to evaluate CSJ117 efficacy and safety on airway … WebApr 13, 2024 · Study Description. To assess the effects of REGN3500, dupilumab, and REGN3500 plus dupilumab, compared with placebo, on changes in inflammatory gene expression signatures in sputum induced after a bronchial allergen challenge (BAC) in adults with mild allergic asthma, at week 4 after treatment initiation compared with those at … WebFeb 20, 2024 · CSJ117 has been evaluated in a Phase I bronchoprovocation study that has assessed its safety, tolerability, … nothum parts